Navigation Links
Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib,Combination Studies

p>

"The results of these combination studies demonstrated that seliciclib could be safely combined with gemcitabine/cisplatin or docetaxel with evidence of anti-tumor activity. However the contribution of seliciclib to the anti-tumor activity of the combinations could not be adequately evaluated in a non-randomized study. To assess the anti-tumor activity of seliciclib as a single agent, we are currently conducting a double-blinded, randomized, Phase II study of single agent seliciclib versus best supportive care in patients with advanced NSCLC who have had at least two prior systemic therapies (the APPRAISE study). In addition, we are currently planning a randomized Phase II study of single agent seliciclib in patients with previously treated nasopharyngeal cancer (NPC)", commented Dr. Judy Chiao, Vice President of Clinical Development and Regulatory Affairs of Cyclacel.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Two Cyclacel drugs are in Phase II trials: sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside analog, for the treatment of cutaneous T-cell lymphoma (CTCL) and seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, for the treatment of lung cancer. Sapacitabine is also in Phase I trials in patients with hematologic malignancies. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is at the IND stage. Several additional programs are at an earlier stage.

Please visit http://www.cyclacel.com/cyc/investors/news/pressreleases for additional information.

Note: The Cyclacel logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actua
'"/>




Page: 1 2 3

Related medicine technology :

1. Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting
2. Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:9/5/2008)...W.Va., Sept. 5 /PRNewswire-USNewswire/ -- Cancer p... fog known as chemobrain. Now in,animal studies at...ered,that injections of N-acetyl cysteine (NAC), a...east cancer chemotherapy drugs sometimes induce., ...eptember issue of the,journal Metabolic Brain Dise...
(Date:9/5/2008)...ANCISCO, Calif., Sept. 5 /-... small molecule LFA-1 inhibitors,to treat inflamma...Nasdaq:,SNSS) today announced SARcode,s initiation...FA-1 product candidate for T-cell mediated ophthal...icense agreement providing,SARcode with an exclusi...
(Date:9/5/2008)...nstrates microRNAs Extracted From a Simple Blood D...cal Biomarkers for a Wide Range of ...echnology, Rosetta Genomics is Currently Developin... Cancer, REHOVOT, Israel and JERSEY CITY, New Jer... Genomics, Ltd. (NASDQ: ROSG), a leader in,the dev...
(Date:9/4/2008)...ed orphan designation for the treatment of Acute M...RINCETON, N.J., Sept. 4 /- Celator Ph... Drug Administration (FDA) has granted orphan,drug...Liposome Injection,for the treatment of Acute Myel...ng to conduct two randomized Phase 2,studies with ...
Breaking Medicine Technology:Study Suggests a Possible Way to Offset Chemobrain Memory Loss 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2Virtual game helps children escape realities of burn unit 3211 1Virtual game helps children escape realities of burn unit 3211 2Revisions to College Cost Reduction and Access Act will create barriers to primary care 3209 1Revisions to College Cost Reduction and Access Act will create barriers to primary care 3209 2Seven Finalists Announced for 2007 Insight Award for Customer Advocacy in Healthcare 3208 1Nursesavvy com Promoting Quality Healthcare for Everyone 3206 1Nursesavvy com Promoting Quality Healthcare for Everyone 3206 2
...uest Therapeutics,Inc., a specialty pharmaceutica...ammatory and infectious diseases, today announced,... of Vascana,– a topical formulation designed... its primary end point and demonstrated statistica...reat patient,population. Typically, a probability...
...rogress and upcoming,milestones on its insulin pro...ll/ - SemBioSys,Genetics Inc. , a biotechnology co...ns for metabolic and cardiovascular disease,today...e,development of plant-derived recombinant human i...67th Scientific Sessions of the,American Diabetes ...
Other Medicine Technology:MediQuest Concludes Confirmatory Phase III Study of Raynaud’s,Therapy 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 4
(Date:9/5/2008)...., Sept. 5 /PRNewswire-USNewswire/ -- The Health R...announced $39 million in grants to,increase and im...ers., "These grants continue President Bush,s his...e services now reach more economically,vulnerable ...fore," HRSA,Administrator Elizabeth M. Duke said. ...
(Date:9/5/2008)...l on John McCain to commit to develop a National A...UL, Minn., Sep. 5 /PRNewswire-USNewswire/ -- The,R... with no mention of the,domestic AIDS epidemic in ...e epidemic overseas. Neither Presidential nominee .... Sarah Palin mentioned AIDS in their remarks,to C...
(Date:9/5/2008)... N.Y., Sept. 5 /PRNewswire/ -- Tonight is a moment...s, entertainment industry,executives, celebrities ...nt advocacy join forces to Stand Up to Cancer. Thi...om 8:00 p.m. to 9:00 p.m. ET on the three,networks...atform to elevate,the discussion about cancer and ...
(Date:9/5/2008)...ept. 5 /PRNewswire-USNewswire/ -- As the general e...onal Federation of Independent,Business ( http://w...andidates for a greater focus on the healthcare co...and Republican conventions are over, NFIB,is askin...t obstacles faced,by small businesses as they furt...
Breaking Medicine News(10 mins):Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3Health News:The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years 2Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 2Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 3
...ge that victims of the terrible 'Elephant Man' cli... a 'reckless' rate.// The drug, a monoclonal anti...mia, multiple sclerosis and rheumatoid arthritis. ...t the victims had been injected 15 times faster th...
...lf of all children in the most rural counties of t...eas, according to a new study //by HHS Agency for ...published in the September-October 2006 issue of A... was led by AHRQ’s Frances Chevarley, Ph.D., analy...
...s can be treated with a low-priced antibiotic, acc...the limbs or scrotum. // A team of scientists at t...t doxycycline gave some relief to patients in the ...e. In addition, the antibiotic killed the causativ...
...earch has revealed that it is tougher to quit ment...be the reason for the excessive smoking-related di...lished in the Archives of Internal Medicine.Nearly...thol cigarettes like Kool or Newport in comparison...
Other Medicine News:Health News:Catastrophic Elephant Man Drug Trial Victims Injected Recklessly 2Health News:Local Health Care Limited for Rural Children 2Health News:Menthol cigarettes harder to quit than regular cigarettes 2
Hemispheric Sound Technology, multi-frequency, linear micro-surgery transducer. This unique tiny transducer is very helpful in tight situations. It has proven to be a choice transducer for pediatric
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer.
Super High Density, multi frequency Side Fire "T intraoperative transducer. A narrower field of view is this transducers benefit for when scanning in smaller abdomens or in tighter spaces.
Super High Density, 120 field of view, angled handle, multi-frequency, convex endovaginal transducer.
Medicine Products: